Takeda Pharmaceutical Co Ltd: Q1 FY2021 Financial Summary (Revised)
Business Context and Reporting Period
This Form 6-K, filed on August 6, 2021, reports a revision to the Summary of Financial Statements for the three-month period ended June 30, 2021 (Q1 FY2021). The revision was necessitated by a subsequent event: a decision by the Irish Tax Appeals Commission on July 30, 2021, upholding a tax assessment regarding a break fee received by Shire plc from AbbVie in 2014. Takeda recorded a non-recurring tax charge of 62.7 billion JPY (including interest) net of 0.5 billion JPY in tax benefits. This charge relates to a condition existing as of June 30, 2021, but does not impact Core or Underlying financial results.
Key Financial Metrics
| Metric (JPY Millions) | Q1 FY2021 (Revised) | Q1 FY2020 | Change (%) |
|---|---|---|---|
| Revenue | 949,603 | 801,850 | 18.4% |
| Operating Profit | 248,552 | 167,285 | 48.6% |
| Profit Before Tax | 222,978 | 130,291 | 71.1% |
| Income Tax Expenses | (85,252) | (47,772) | 78.5% |
| Net Profit for the Period | 137,726 | 82,519 | 66.9% |
| Net Profit (Attributable to Owners) | 137,684 | 82,511 | 66.9% |
| Basic EPS (JPY) | 87.96 | 52.93 | 66.2% |
Balance Sheet (as of June 30, 2021): Total Assets were 12,657 billion JPY; Total Equity was 5,239 billion JPY. Cash and cash equivalents stood at 655 billion JPY. Total Bonds and Loans were 4,406 billion JPY.
Cash Flow: Net cash from operating activities was 167 billion JPY. Net cash used in financing activities was 411 billion JPY, driven by debt repayments.
Material Changes and Drivers
- Revenue Growth: Reported revenue increased 18.4% year-over-year. This includes a one-time 133.0 billion JPY gain from the sale of a diabetes portfolio in Japan. Excluding this sale and foreign exchange effects, underlying revenue growth was 3.8%.
- Operating Profit: Increased 48.6% to 248.6 billion JPY, driven by strong performance in Gastroenterology (ENTYVIO) and Oncology (VELCADE), partially offset by higher R&D expenses and SG&A costs due to yen depreciation.
- Tax Impact: The revised net profit reflects a 62.7 billion JPY tax charge related to the Irish tax assessment on the Shire break fee. Without this charge, net profit would have been significantly higher.
- Core Metrics: Core Operating Profit remained stable at 248.9 billion JPY. Underlying Core Operating Profit declined 2.1% due to increased R&D investment, while Underlying Core EPS grew 3.9%.
Guidance, Outlook, and Risks
Full Year FY2022 Forecast (Ending March 31, 2022):
- Revenue: 3,370 billion JPY (+5.4% YoY).
- Operating Profit: 488 billion JPY (-4.2% YoY).
- Net Profit: 250 billion JPY (-33.5% YoY), heavily impacted by the one-time Irish tax charge.
- Core EPS: 394 JPY (-6.2% YoY).
Management Guidance (Underlying):
- Underlying Revenue Growth: Mid-single-digit.
- Underlying Core Operating Profit Growth: Mid-single-digit.
- Underlying Core Operating Profit Margin: ~30%.
Risks and Contingencies:
- Tax Litigation: The Irish tax assessment is a non-recurring item but significantly reduced reported net profit for the quarter and full year.
- COVID-19: While not materially impacting Q1 results, the company notes potential risks regarding supply chains, clinical trial delays, and demand slowdowns if lockdowns extend.
- Competition: Anticipated launch of a 505(b)2 competitor for subcutaneous VELCADE in the U.S. mid-FY2021.
- Divestitures: Ongoing divestitures of non-core assets (e.g., diabetes portfolio) impact comparability.
Investor Verification Checklist
- Verify the impact of the 62.7 billion JPY Irish tax charge on the full-year net profit forecast and confirm it is excluded from Core/Underlying metrics.
- Assess the sustainability of revenue growth excluding the 133.0 billion JPY one-time gain from the Japan diabetes portfolio sale.
- Monitor the "Underlying" growth metrics (Revenue +3.8%, Core EPS +3.9%) as the primary indicator of operational performance.
- Review the debt reduction strategy, noting the repayment of 2.2 billion USD in loans and bonds during the quarter.
- Track the competitive landscape for key products like VELCADE and ENTYVIO, particularly regarding generic erosion and new entrants.